Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR
- 1 November 1997
- journal article
- review article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 15 (6) , 398-408
- https://doi.org/10.1002/stem.150398
Abstract
Several important functions have been assigned to the receptor for urokinase‐type plasminogen activator, uPAR. As implied by the name, uPAR was first identified as a high affinity cellular receptor for urokinase plasminogen activator (uPA). It mediates the binding of the zymogen, pro‐uPA, to the plasma membrane where trace amounts of plasmin will initiate a series of events referred to as “reciprocal zymogen activation” where plasmin converts pro‐uPA to the active enzyme, uPA, which in turn converts plasma membrane‐associated plasminogen to plasmin. This is an efficient machinery to generate broad‐spectrum proteolytic activity which is spatially restricted to the plasma membrane, since plasmin that diffuses away from the plasma membrane is rapidly inactivated by circulating inhibitors (i.e., α2‐antiplasmin). The system is controlled by a series of plasminogen activator inhibitors (PAIs), most importantly PAI‐1 and PAI‐2, providing means of temporally restricting the process of plasminogen activation. In addition to its role in plasminogen activation, compelling evidence has demonstrated a role for uPAR in cell‐cell and cell‐extracellular matrix adhesion, both directly and indirectly. uPAR is directly involved in binding to the extracellular matrix molecule, vitronectin, and the affinity of this binding is increased when uPAR is occupied by (pro‐)uPA. A more indirect but presumably very important role of uPAR in cell adhesion seems to be mediated through interactions between uPAR and β1‐ or β2‐integrins. It has been demonstrated that uPAR may bind physically to integrins in a reversible manner. The interaction seems to be of functional importance since the affinity of the integrin for its corresponding ligand is modulated by the association of integrin with uPAR. In some experimental setups uPAR has been shown to reduce the affinity of the associated integrin for certain ligands, while other experimental systems have demonstrated an increased affinity of the interaction between integrin and ligand after binding of uPAR to the integrin. Finally, uPAR has also been shown to participate in signal transduction events. Since uPAR is not a transmembrane molecule but belongs to the group of proteins that are tethered to the plasma membrane via a glycosyl‐phosphatidylinositol anchor, association with a transmembrane adaptor is required for transmission of signals via uPAR. Integrins may serve as such signal transducers, and indeed uPAR has been shown to be associated in the plasma membrane with complexes of integrins and (phosphorylated) tyrosin kinases suggesting a role for these complexes in transmembrane transmission of signals via uPAR. In the hematopoietic system it has been shown that urokinase‐type plasminogen activator (uPAR) is expressed as a differentiation antigen on cells of the myelomonocytic lineage and as an activation antigen on monocytes and T lymphocytes. Neutrophils contain intracellular reservoirs of uPAR that are translocated to the plasma membrane upon activation, and neutrophils from patients with the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) that fail to express glycosyl‐phosphatidylinositol‐anchored proteins including uPAR, show a very significantly reduced transmigration over an endothelial barrier. Cell‐associated plasminogen activation by PNH‐affected neutrophils is severely impaired, and it has been proposed that this may be causally related to the propensity for thrombosis in PNH. The pattern of expression of uPAR in hematological malignancies mirrors the expression by normal blood and bone marrow counterparts with some exceptions (differentiated myeloid leukemias are positive, undifferentiated myeloid may be negative and the majority of lymphoid leukemias and lymphomas are negative). The potential clinical relevance of uPAR expression in leukemias and lymphomas has not been determined.Keywords
This publication has 100 references indexed in Scilit:
- Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxinsFEBS Letters, 1994
- Transforming growth factor‐β1 stimulates macrophage urokinase expression and release of matrix‐bound basic fibroblast growth factorJournal of Cellular Physiology, 1993
- Interaction of urokinase‐type plasminogenactivator (u‐PA) with its cellular receptor (u‐PAR) induces phosphorylation on tyrosine of a 38 kDa proteinFEBS Letters, 1993
- The urokinase receptor and regulation of cell surface plasminogen activationCell Differentiation and Development, 1990
- Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.The Journal of cell biology, 1989
- Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.The Journal of cell biology, 1988
- Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophilsBiochemical and Biophysical Research Communications, 1987
- Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cellsThe Journal of cell biology, 1987
- Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis.The Journal of Experimental Medicine, 1986
- Leukocyte-Plasma Interaction in FibrinolysisNew England Journal of Medicine, 1979